TY  - JOUR

T1  - Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with <i>FGFR3</i> alterations (trial in progress)

JO  - Cancer Research

UR  - http://dx.doi.org/10.1158/1538-7445.am2023-ct119

PY  - 2023/04/14

AU  - Iyer G

AU  - Siefker-Radtke A

AU  - Milowsky M

AU  - Shore N

AU  - Gao X

AU  - Reimers MA

AU  - Hahn N

AU  - Cosman R

AU  - Matsubara N

AU  - Necchi A

AU  - Robbrecht D et al

ED  - 

DO  - DOI: 10.1158/1538-7445.am2023-ct119

PB  - American Association for Cancer Research (AACR)

VL  - 83

IS  - 8_Supplement

SP  - CT119

EP  - CT119

Y2  - 2024/12/21

ER  -